Kiniksa Pharmaceuticals Q3 2024 GAAP EPS $(0.18) May Not Be Comparable To $0.04 Estimate, Sales $112.21M Beat $111.52M Estimate
Kiniksa Pharmaceuticals Q3 2024 GAAP EPS $(0.18) May Not Be Comparable To $0.04 Estimate, Sales $112.21M Beat $111.52M Estimate
kiniksa pharmaceuticals 2024年第三季度的GAAP每股收益爲$(0.18)，可能與0.04的預估不可比較，銷售額爲11221萬，超過11152萬的預估
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $0.04 by 550 percent. The company reported quarterly sales of $112.21 million which beat the analyst consensus estimate of $111.52 million by 0.62 percent. This is a 67.37 percent increase over sales of $67.05 million the same period last year.
kiniksa pharmaceuticals（納斯達克：KNSA）報告每股虧損$(0.18)，較分析師一致預期的$0.04低550％。該公司報告的季度銷售額爲$11221萬，超過分析師一致預期的$11152萬，增長0.62％。這是銷售額比去年同期的$6705萬增長了67.37％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間